THEORETICAL ARTICLE

Treatment-resistant depression: A systematic review of systematic reviews

Alia Inés Pérez-Wehbea,*, Lilisbeth Perestelo-Pérezb, Juan Manuel Bethencourt-Pérezc, Leticia Cuéllar-Pompad, Wenceslao Peñate-Castrod

a Grupo Sanitario ICOT, Centro Sociosanitario El Pino, Gran Canaria, Spain
b Servicio de Evaluación del Servicio Canario de la Salud – Red de Investigación en Servicios de Salud en Enfermedades Crónicas [REDISSEC], Spain
c Universidad de La Laguna, Spain
d Fundación Canaria de Investigación y Salud [FUNCIS], Spain

Received July 11, 2013; accepted February 5, 2014

Abstract  The objective of this research study was to assess pharmacological, somatic and/or psychological treatments in adults with a diagnosis of major depressive disorder who have not responded to at least one course of antidepressant medication. We conducted a systematic review to identify systematic scientific reviews and meta-analyses on treatment-resistant depression (TRD) published until February 2012. Of the sixty studies selected, sixteen met the inclusion criteria and were therefore included in the review. We considered eight main themes, including the definition of TRD, long-term results, and different treatment strategies, including so-called somatic therapies. Based on the review, the definition of TRD should be standardized in order to achieve a shared conceptualization of this disorder. This would allow a better understanding among clinicians and researchers in the field, promoting a homogeneous research methodology and thus leading to more reliable and comparable results. This essential conceptual clarification would also have a positive impact on patients with TRD, their families, and social and health systems.

© 2013 Asociación Española de Psicología Conductual. Published by Elsevier España, S.L. All rights reserved.

KEYWORDS  Treatment-resistant depression; Refractory depression; Treatment; Systematic review; Theoretical study

Resumen  El objetivo de esta investigación es analizar la literatura científica sobre los tratamientos farmacológicos, somáticos y/o psicológicos en adultos con diagnóstico de un trastorno depresivo mayor que no han respondido al menos a un tratamiento con antidepresivos. Se llevó a cabo una revisión sistemática sin limitación temporal para identificar las revisiones sistemáticas y meta-análisis publicados hasta febrero de 2012 en DRT. Sesenta estudios fueron seleccionados de entre los cuales quedaron incluidos dieciséis al cumplir con los criterios de inclusión. Se sintetizan ocho temas principales entre los que cabe destacar la definición, resultados a

*Corresponding author at: Grupo Sanitario ICOT, Centro Sociosanitario El Pino, Av. Juan XXIII, 13, 35004 Las Palmas de Gran Canaria, Spain.
E-mail address: aperrez@grupoicot.es (A.I. Pérez-Wehbe).

1697-2600/$ - see front matter © 2013 Asociación Española de Psicología Conductual. Published by Elsevier España, S.L. All rights reserved.
Depression is one of the most common mental disorders in current Western societies. At present, it continues to grow in numbers and is one of the main causes of disability around the world, particularly in high-income regions (e.g., Davidson, 2010; McKenna, Michaud, Murray, & Marks, 2005; World Health Organization [WHO], 2005). To deal with this relevant health and social problem, there are several efficient interventions such as use of antidepressant drugs (ADs; Geddes et al., 2003; Perestelo-Pérez et al., 2010) and psychological treatments, particularly those derived from a cognitive-behavioural approach (Aguilera, Garza, & Muñoz, 2010; Kaltenthaler et al., 2006; Merry, McDowell, Hetrick, Bir, & Muller, 2004). Despite these efficient treatment tools, up to 50% of individuals with depression do not show significant clinical recovery. Hence, a large proportion of the burden caused by depression has been attributed to ‘treatment-resistant depression’ (TRD; Álvarez et al., 2008; Eby & Eby, 2010; Jenkins & Goldner, 2012).

TRD is most likely to occur with comorbid physical and mental disorders as well as marked and protracted functional impairment. It is highly recurrent, with as many as 80% of patients who require multiple treatments relapsing within a year of remission and a probability of recovery of about 40% within 10 years. Thus, TRD is the subject of a considerable amount of research aimed at reducing the substantial burden and high healthcare costs it originates (Fekadu et al., 2009).

As happens with other depressive disorders, there are different treatment approaches to TRD. New protocols and treatment resources have been developed to treat this disorder. A few examples are combination or augmentation strategies (Mahmoud et al., 2007; Shelton, Osuntokun, Heinloth, & Corya, 2010; Vigo & Baldessarini, 2009) and repetitive transcranial magnetic stimulation (rTMS; Padberg & George 2009; Schlaepfer, George, & Mayberg, 2009). Despite these efforts, the situation remains unclear and no specific protocol is recommended to treat TRD (National Institute for Health and Clinical Excellence [NICE], 2009).

The aim of the present systematic review (SR) was to identify published systematic reviews (SRs) and meta-analyses to assess pharmacological, somatic and/or psychological treatments in adults with a diagnosis of major depressive disorder who have not responded to at least one course of antidepressant medication. We conducted this SR based on the recommendations of Fernández-Ríos and Buela-Casal (2009) and Perestelo-Pérez (2013).

Method

Search strategy

We systematically reviewed materials published until September 2012, consulting the following databases: Medline, Medline In-Process, Old Medline, Embase, Cochrane, Cinahl, and PsycINFO. We developed a search strategy for each electronic database using the combination of the following Medical Subject Heading (MeSH) and free-text terms: pharmacology, antidepressant, psychology, psychotherapy, psychopharmacology, combination, depression, depressive disorders, systematic, review, and the names of individual antidepressants and individual psychotherapies. An experienced information specialist developed, tested, and refined the search strategies with input from the authors (full details are available on request).

To complete the information sources, we scrutinized reference lists of selected review papers manually for further relevant articles and reports. We increased the number of articles available by conducting additional searches on the Internet and in book chapters and contacting relevant authors in the field.

Inclusion and exclusion criteria

The scientific articles included in the SR were systematic reviews (SRs) and meta-analyses on TRD assessing the efficacy of pharmacological, somatic and/or psychological treatments for TRD with the aim of directly or indirectly improving patients’ depressive state. No language restrictions were applied. Intra-group comparison studies, narrative reviews, case studies, and expert consensus studies were excluded.

Studies included were those in which participants were adults up to 65 years old with a depressive disorder according to the diagnostic criteria of the International Statistical Classification of Diseases and Related Health Problems (CIE-10; World Health Organization, 1992) or the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association [APA], 2000); participants had to suffer from TRD, understood as depression that had not responded to two adequate antidepressant treatments, or be recruited according to their scores in a validated questionnaire measuring depression such as the Montgomery–Asberg Depression Rating Scale (MADRS, Montgomery & Asberg, 1979) or the HAM-D rating scale (Hamilton, 1960).

Studies excluded were those in which participants had any of the following: an episode or disorder attributable to...
the consumption of psychoactive substances or to a medi-
cal illness, a history of episodes of hypomania, mania, or a
combination of both, a cyclothymic disorder, a new major
Depressive episode or one superimposed to or better ex-
plained by another mental disorder, any other organic men-
tal disorders, or pregnancy-related depression. Studies in-
volved in infant, youth, or geriatric patients were also ex-
cluded.

Study selection process

The study selection process was carried out separately by
two reviewers to reduce the possibility of rejecting rele-
vant articles. Reviewers used the following blinded and
structured hierarchical strategy: first, reading titles
and abstracts; second, reading the articles selected in the
first phase in full; third, selecting articles fulfilling the spe-
cific inclusion criteria. If any discrepancies arose, a third
reviewer verified the selection criteria and a consensus was
reached.

Data extraction

Data were extracted independently by the same research-
ers who selected the studies, who received previous train-
ing for this purpose. Any disagreements were solved by con-
sensus with the help of a third reviewer. The following
information was extracted from each of the SRs considered:
databases consulted, use of a manual search or not, time
period reviewed, study inclusion criteria, number of studies
and sample size, main objective of the SR, and main con-
clusions of the SR.

Quality assessment

Each article was critically assessed according to its meth-
odological quality. To select articles of scientific value
meeting the pre-specified inclusion and exclusion criteria
and reduce bias, SRs had to exceed at least 50% of the max-
imum score of the scale (Oxman ≥ 5). Two reviewers inde-
pendently assessed included studies using the Oxman Scale
(Oxman, Cook, & Guyatt, 1994). In this scale, scores range
from 0 to 10 points; higher scores indicate a better quality.
The scale assesses five areas: i) definition of the subject of
study of the review (2 points); ii) selection of review arti-
cles (2 points); iii) importance and relevance of articles re-
viewed (2 points); iv) assessment of the quality of studies
reviewed (2 points); and v) combined results of studies re-
viewed (2 points).

Any doubts or disagreements between both reviewers
were resolved by verifying the protocol criteria and subse-
quently reaching consensus.

Results

Identified studies

Using the search strategy described above, we identified a
total of 21,446 references. After eliminating duplicates, we
retained 13,367 references. Of these references found as
of February 2012, 103 were selected by title and abstract.
The search and selection process used to identify referenc-
es is shown in Figure 1.

Given the large number of SRs identified, we decided to
limit the review period to cover SRs published since the
year 2000, assuming that they would include relevant infor-
mation from previous years.

Included and excluded studies

Of the 60 SRs selected and read in full, the following 16
were included: Barowsky & Schwartz, 2006; Bauer,
Tharmanathan, Volz, Moeller, & Freemantle, 2009; Ber-
lim & Turecki, 2007; Bschor & Baethge, 2010; Bschor &
Bauer, 2006; Daban, Martinez-Aran, Cruz, & Vieta, 2008;
We excluded 44 references from this review because they were not systematic reviews or did not meet some of the other inclusion criteria described in the protocol.

### Methodological quality

Table 1 shows the methodological quality scores of the systematic reviews included according to the Oxman Scale (Oxman, Cook, & Guyatt, 1994).

### Characteristics of included studies

Based on the data extraction sheet, we developed Table 2, identifying the main characteristics of the studies, and Table 3, showing the main objective of the systematic reviews included.

Of the 16 SRs included, 13 understood TRD as failure to respond to an antidepressant treatment, one included a partial response to such treatment (Lam et al., 2008) and 6 understood TRD as failure to respond to one or more ADs (Berlim & Turecki, 2007; Bschor & Bauer, 2006; Fekadu et al., 2005; Lam et al., 2002; McPherson et al., 2005; Thomas et al., 2010). Two SRs (Barowsky & Schwartz, 2006; Sarnecki & Temel, 2011) considered Thase and Rush stages (1997) and one SR dealt with TRD staging methods. Table 2 identifies the characteristics of the studies and Table 3 shows the main objective of the SRs included.

The main findings obtained for each SR are shown in Table 4, clustered into eight different themes.

### Definition of treatment-resistant depression and staging methods

Overall, results of randomized controlled trials (RCTs) differed in most of the conceptual and methodological issues related to TRD. Among five staging methods found in the literature, the Thase and Rush method was the most widely used.

### Long-term results

Although TRD is associated with worse clinical course and clinical and social consequences, its long-term evolution is based on a heterogeneous group of studies of limited methodological quality.

### Venlafaxine

Studies provide evidence of the clinical efficacy of this drug in achieving therapeutic response and remission of symptoms. Venlafaxine appears to be more effective than selective serotonin reuptake inhibitors (SSRIs) and at least as effective as tricyclic ADs.

### Switching ADs

There is a discrepancy between published evidence and the decision to switch ADs frequently in clinical practice.

### Combining ADs

Combining ADs with different mechanisms of action is a strategy that seems effective. In fact, some success has

---

### Table 1 Quality level of SRs included according to the Oxman Scale.

<table>
<thead>
<tr>
<th>Author</th>
<th>Oxman 1</th>
<th>Oxman 2</th>
<th>Oxman 3</th>
<th>Oxman 4</th>
<th>Oxman 5</th>
<th>Total /10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barowsky &amp; Schwartz (2006)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Bauer et al. (2009)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Berlim &amp; Turecki (2007)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Bschor &amp; Bauer (2006)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Bschor &amp; Baethge (2010)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Daban et al. (2008)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Dodd et al. (2005)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Fekadu et al. (2009)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Lam et al. (2008)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Lam et al. (2002)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>McPherson et al. (2005)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Ruhé et al. (2012)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Stimpson et al. (2002)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Sarnecki &amp; Temel (2011)</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Thomas et al. (2010)</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Trivedi et al. (2011)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>8</td>
</tr>
</tbody>
</table>
been observed with combinations of bupropion plus an SSRI, reboxetine plus an SSRI, venlafaxine plus mirtazapine, and a monoaminoxidase inhibitor plus a tricyclic AD.

Augmenting antidepressant drugs

Adding lithium is recommended as a treatment strategy for patients who do not respond adequately to standard treatment with ADs in international guidelines and reviews. However, there is little evidence of the use of other compounds such as lamotrigine.

<table>
<thead>
<tr>
<th>Author</th>
<th>Data base</th>
<th>Manual search</th>
<th>Years</th>
<th>Criteria</th>
<th>Nº Studies (Nº Subjects)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dodd et al. (2005)</td>
<td>Psychlit Medline, Embase, Medline, PsycINFO</td>
<td>Reference section</td>
<td>Up to Jan. 2005</td>
<td>RCTs</td>
<td>24 trials</td>
</tr>
<tr>
<td>McPherson et al. (2005)</td>
<td>Medline, PsycINFO</td>
<td>Reference section</td>
<td>1988 - 2001</td>
<td>All designs and languages</td>
<td>12</td>
</tr>
<tr>
<td>Sarnecki &amp; Temel (2011)</td>
<td>CCTR, Embase, Lilacs, Medline, Psychlit, PsycINFO</td>
<td>Contacting authors</td>
<td>1966 - Jan. 2001</td>
<td>RCTs on treatments</td>
<td>17 (645)</td>
</tr>
<tr>
<td>Stimpson et al. (2002)</td>
<td>Medline</td>
<td>Not conducted</td>
<td>Before March 2010</td>
<td>RCTs</td>
<td>6 studies (50)</td>
</tr>
<tr>
<td>Thomas et al. (2010)</td>
<td>CCTR, CCR, CCTR, Central, Cinahl, Embase, Medline, Embase/Pubmed, PsycINFO</td>
<td>Reference section</td>
<td>1966+</td>
<td>RCTs on lamotrigine</td>
<td>10 (23)</td>
</tr>
<tr>
<td>Trivedi et al. (2011)</td>
<td>CCTR, Embase, PsycINFO, PubMed</td>
<td>Reference section</td>
<td>Up to 07/09/2010</td>
<td>RCTs</td>
<td>13 (592)</td>
</tr>
</tbody>
</table>

Note. AD = Antidepressant; CCTR = Cochrane Central Register of Controlled Trials; CCDANCTR = Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register; CRD = Centre for Reviews and Dissemination; TRD = Treatment-Resistant Depression; VNS = Vagus Nerve Stimulation; rTMS = repetitive Transcranial Magnetic Stimulation; SSRI = Selective Serotonin Reuptake Inhibitor; RCTs = Randomized Control Trials.

Psychological treatments

Although such treatments are commonly used and often recommended after medication has failed, there is little evidence of their effectiveness.

Somatic treatments

Overall, specific parameters of stimulation and side effects are yet to be defined for rTMS and vagus nerve stimulation, the most beneficial deep brain stimulation techniques.
Discussion and conclusions

There are currently many treatment options available once an AD trial has failed (Ruelaz, 2006), such as switching to another AD (Barowsky & Schwartz, 2006; Bschor & Bauer, 2006), combining two ADs of the same or a different class (Dodd et al., 2005; Lam et al., 2002), or augmenting the AD with other pharmacological substances (Gabriel, 2006; Nierenberg et al., 2003; Rocha & Hara, 2003). However, the present SR revealed that the literature available to date does not show consistent results for any of these strategies. We found a discrepancy between published evidence and the frequent decision to switch, combine, or augment antidepressants in clinical practice.

With regard to somatic treatments, only a moderate percentage of patients were found to gain relief with deep brain stimulation techniques, but results should not be generalized as sample sizes are small and a robust research methodology is needed (Kennedy & Giacobbe, 2007). Repetitive transcranial magnetic stimulation (rTMS) appears to provide significant benefits in short-term treatment studies. Yet, the relatively low response and remission rates, short durations of treatment, and relative lack of systematic follow-up studies suggest that further studies are needed before rTMS can be considered as a first-line monotherapy treatment for TRD (Bretlau et al., 2010; Triggs et al., 2010). Vagus nerve stimulation seems to be an interesting new approach to treat TRD, but results are reported mainly in open studies. Therefore, further clinical trials are needed to confirm its efficacy in major depression. Overall, it has not been possible to determine the most beneficial stimulation areas, parameters, and side effects for these three somatic treatments yet.

Table 3 Main objective of SRs included.

<table>
<thead>
<tr>
<th>Author</th>
<th>Objective</th>
<th>Main theme</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barowsky &amp; Schwartz</td>
<td>To establish state of the matter regarding augmentation and combining strategies with lithium, thyroid hormone and other compounds, for TRD</td>
<td>Augmentation and combination</td>
</tr>
<tr>
<td>(2006)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bauer et al. (2009)</td>
<td>Meta-analysis of trials of Venlafaxine in the treatment of MDD, including treatment resistant depression and long term relapse prevention</td>
<td>Venlafaxine</td>
</tr>
<tr>
<td>Bertlin &amp; Turecki (2007)</td>
<td>To summarize and discuss the conceptual and operational definitions of TRD by systematically reviewing RCTs on its somatic treatments</td>
<td>TRD definition</td>
</tr>
<tr>
<td>Bschor &amp; Bauer (2006)</td>
<td>It reviews the clinical evidence and hypotheses on the mode of action of lithium augmentation</td>
<td>Augmentation with Lithium</td>
</tr>
<tr>
<td>Bschor &amp; Baethge (2010)</td>
<td>To summarise the scientific findings on switching antidepressants to manage TRD patients</td>
<td>Switching ADs</td>
</tr>
<tr>
<td>Daban et al. (2008)</td>
<td>To evaluate the safety and efficacy of VNS in TRD</td>
<td>VNS</td>
</tr>
<tr>
<td>Dodd et al. (2005)</td>
<td>To review published trials on combination antidepressants with a view to inform clinical practice</td>
<td>Combining ADs</td>
</tr>
<tr>
<td>Fekadu et al. (2009)</td>
<td>To assess how people with TRD fare in the longer term, from information gathered in observational studies. We were not interested in acute treatment trials of TRD, but in studies which provided data on the longer term outcome of those who either had ongoing depressive symptoms after treatment or who had previously experienced TRD but responded successfully to treatment</td>
<td>Long-term outcomes for TRD patients</td>
</tr>
<tr>
<td>Lam et al. (2008)</td>
<td>To find clear evidence of rTMS for TRD focusing on clinical outcomes that are relevant to clinicians</td>
<td>rTMS</td>
</tr>
<tr>
<td>Lam et al. (2002)</td>
<td>To critically evaluate the evidence for efficacy of combining antidepressants</td>
<td>Combining ADs</td>
</tr>
<tr>
<td>McPherson et al. (2005)</td>
<td>To evaluate psychological interventions with treatment resistant depression</td>
<td>Psychological treatments</td>
</tr>
<tr>
<td>Ruhé et al. (2012)</td>
<td>To identify staging models for TRD and compare them regarding predictive utility and reliability</td>
<td>Staging methods</td>
</tr>
<tr>
<td>Stimpson et al. (2002)</td>
<td>To give a summation of the findings of the clinical studies on DBS and TRD that have been concluded thus far</td>
<td>Deep Brain Stimulation</td>
</tr>
<tr>
<td>Sarnecki &amp; Temel (2011)</td>
<td>To summarise the findings from all RCTs that have assessed the efficacy of a pharmacological or psychological intervention for TRD</td>
<td>Pharmacological and psychological interventions</td>
</tr>
<tr>
<td>Thomas et al. (2010)</td>
<td>To review all the evidence of lamotrigine’s effectiveness in treatment resistant depression after at least one failed antidepressant trial</td>
<td>Augmentation with Lamotrigine</td>
</tr>
<tr>
<td>Trivedi et al. (2011)</td>
<td>To examine the utility of psychotherapy in managing treatment resistant depression</td>
<td>Psychotherapy</td>
</tr>
</tbody>
</table>

Note. AD = Antidepressant; TRD = Treatment-Resistant Depression; MDD = Major Depressive Disorder; VNS = Vagus Nerve Stimulation; rTMS = repetitive Transcranial Magnetic Stimulation; RCTs = Randomized Control Trials.
Main findings of individual SRs included.

<table>
<thead>
<tr>
<th>Study</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barowsky &amp; Schwartz</td>
<td>The idea that the most common augmentation strategies in depression are those with the least controlled evidence highlights the fact that much of psychopharmacology is also an “art” in which clinicians prescribe based on anecdotal experience of positive patient responses based on particular depressive symptoms.</td>
</tr>
<tr>
<td>Bauer et al. (2009)</td>
<td>Venlafaxine appears superior to SSRIs for both response and remission, with similar overall tolerability, derived from a lower rate of drop out for inefficacy and a higher rate of drop out from side effects.</td>
</tr>
<tr>
<td>Berlim &amp; Turecki (2007)</td>
<td>Overall, RCTs diverged regarding the majority of the conceptual and methodological issues involved in the ascertainment of TRD, this is: 1) number and type of previous failed trials needed to establish a diagnosis of TRD, definition of treatment adequacy (dose, titration, and duration), the definition of treatment response, and the assessment of primary and comorbid diagnoses.</td>
</tr>
<tr>
<td>Bschor &amp; Bauer (2008)</td>
<td>Lithium augmentation is recommended as a first-line treatment strategy for patients with a major depressive episode who did not adequately respond to standard antidepressant treatment in international guidelines and (2006) reviews. Is the response to lithium augmentation a “true” augmentation effect, resulting from a specific pharmacological interaction between lithium and the antidepressant, or is it simply the antidepressant effect of lithium alone?</td>
</tr>
<tr>
<td>Daban et al. (2008)</td>
<td>VNS seems to be an interesting new approach to treating TRD. However, despite the promising results reported mainly in open studies, further clinical trials are needed to confirm its efficacy in major depression.</td>
</tr>
<tr>
<td>Dodd et al. (2005)</td>
<td>Data suggests that combining antidepressants with different mechanisms of action is a worthwhile strategy with some observed success with combinations of bupropion plus an SSRI, reboxetine plus an SSRI, mirtazapine plus venlafaxine, and a MAOI plus a TCA.</td>
</tr>
<tr>
<td>Fekadu et al. (2009)</td>
<td>TRD is associated with poorer clinical outcome, particularly among those who require multiple antidepressant medications. The main limitations of the review arise from the variability in recruitment procedures, definitions and outcome assessments of the original studies.</td>
</tr>
<tr>
<td>Lam et al. (2002)</td>
<td>For patients with TRD, rTMS appears to provide significant benefits in short-term treatment studies. However, the relatively low response and remission rates, the short durations of treatment, and the relative lack of systematic follow-up studies suggest that further studies are needed before rTMS can be considered as a first-line monotherapy treatment for TRD.</td>
</tr>
<tr>
<td>Lam et al. (2008)</td>
<td>Given the high rates of inadequate response to current treatments, it is important to better evaluate the efficacy of combination antidepressant treatment. Future RCTs should incorporate study designs that are more likely to determine efficacy vs. monotherapy with the second drug.</td>
</tr>
<tr>
<td>McPherson et al. (2005)</td>
<td>Psychological treatments for depression are commonly delivered and often recommended following the failure of medication. The paucity of evidence for their effectiveness in these situations is a significant problem. There is a need for studies with a strong controlled design investigating the effectiveness of psychological treatments for patients with treatment-resistant depression.</td>
</tr>
<tr>
<td>Ruhé et al. (2012)</td>
<td>Despite validation of the MSM, further investigation of the reliability and predictive utility of TRD staging models and additional disease characteristics is required. Correct staging of TRD might improve generalizability of results from clinical studies and improve delivery of care to TRD patients. They propose methods to validate staging models in TRD.</td>
</tr>
<tr>
<td>Sarnecki &amp; Temel (2011)</td>
<td>Treatment-refractory depression is common in clinical practice but there is little evidence to inform management. There was some evidence of benefit for lithium augmentation, but the evidence was very weak. In the absence of good evidence, clinicians will have to rely upon their own clinical judgement in deciding upon treatment.</td>
</tr>
<tr>
<td>Stimpson et al. (2002)</td>
<td>Only a moderate percentage of patients gained relief. However, sample sizes were small and a lack of proper research methodology was apparent; as a consequence, the most beneficial stimulation areas, parameters and its side-effects are not yet determinable.</td>
</tr>
<tr>
<td>Thomas et al. (2010)</td>
<td>There is little evidence to guide the use of lamotrigine for depression that has not responded to a course of antidepressants.</td>
</tr>
<tr>
<td>Trivedi et al. (2011)</td>
<td>There is a pressing need to examine psychotherapy as a second step treatment in patients who have not responded to initial antidepressants treatment. This may be addressed in two ways: 1) re-analysis of existing data from trials in which patients with treatment resistant depression are recruited, or 2) conducting studies designed to examine this question. As a field, it is important to develop a standardized, operational definition of treatment resistant depression to facilitate comparisons across studies.</td>
</tr>
</tbody>
</table>

Note. TRD = Treatment-Resistant Depression; VNS = Vagus Nerve Stimulation; SSRI = Selective Serotonin Reuptake Inhibitor; MAOI = Monoamine Oxidase Inhibitors; MSM = Maudsley Staging Method; TCA = Tricyclic Antidepressants; VNS =: Vagus Nerve Stimulation; rTMS = Transcranial Magnetic Stimulation; RCTs = Randomized Control Trials.
Data about psychological treatments for depression show that they are commonly delivered and recommended following the failure of medication, but the scarce evidence of their effectiveness in these situations is a significant problem (Anderson, Nutt, & Deakin, 2000; Parker, Blanch, & Crawford, 2010). There is a need for studies with a strong controlled design exploring the effectiveness of psychological treatments for patients with TRD and assessing psychotherapy as a second step treatment in patients not responding to initial treatment with antidepressants. It is also important to develop a standardized, operational definition of TRD to facilitate comparisons across studies (McPherson et al., 2005).

Although it was not the main aim of this research, this systematic review revealed, in line with many research studies (e.g., Bschor & Bauer, 2006; Catafau et al., 2001; Kennedy & Giacobbe, 2007; O’Reardon, Thase, & Papakostas, 2009), a considerable heterogeneity regarding most conceptual and methodological issues involved in the ascertainment of TRD in the published literature. More specifically, there are major differences in the number and type of previous failed trials required to make a diagnosis of TRD, the definition of treatment adequacy (dose, titration, and duration) and treatment response, and the assessment of primary and comorbid diagnoses. As regards the five staging methods found by our SR in the literature, the Thase and Rush method (1997) and the Maudsley Staging Method (Fekadu et al., 2009) were those most widely used. However, it is necessary to further explore the reliability and predictive utility of TRD staging models and additional disease characteristics. In this regard, the NICE (2009) proposes understanding TRD from a dimensional perspective for patients who show an inadequate response to treatment. This approach starts with the least intrusive intervention and patients who do not show any response are offered a sequenced structured intervention in several consecutive steps. It should be noted that patients who show a poor response to treatment are also considered in this new conceptualization.

It is important to note that conclusions are limited to the information and methodological quality of the available scientific evidence included in this SR. In addition, the authors consider that the articles published omit information of particular interest in the case of TRD that might be relevant to the interpretation of results (e.g., comorbidity with other disorders or physical or mental illness). In this regard, some of the first articles selected were excluded because they did not include a definition of TRD. In this research, TRD was understood as failure to respond to one or more AD treatments. Therefore, conclusions are to be reached only within this context.

**Funding**

This work was supported by a grant from the Canary Islands Foundation for Health Research (FUNCIS; Exp. 51/09).

**References**

(References with * are studies included in systematic review)


